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Anti-neutrophil cytoplasm antibody (ANCA)–associated
vasculitis frequently presents with renal involvement
manifested by a focal segmental necrotizing
glomerulonephritis, which is typically pauci-immune.
Although considerable insight has been gained regarding
potential mechanisms of organ damage, researchers
have remained relatively ignorant of the initiating factors
breaking immune tolerance. A recent report has provided
evidence that molecular mimicry may be critical, with
immune responsiveness toward a bacterial fimbrial protein
inducing a cross-reactive autoimmune response toward
lysosomal-associated membrane protein-2 (LAMP-2). Use
of an experimental model demonstrates that this response
generates ANCA and provokes pulmonary-renal disease,
reminiscent of human ANCA–associated vasculitis. Greater
understanding of the immune mechanisms underlying
the development of ANCA should lead to more focused
approaches to the treatment of small-vessel vasculitis.
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In their original report of a new autoantibody associated
with pauci-immune glomerulonephritis, termed the ‘anti-
neutrophil cytoplasm antibody (ANCA)’, Davies et al.1
described eight patients who showed this antibody, of whom
seven showed reactivity to Ross River virus. The authors
suggested that the antibody resulted from an infection with
this type of arbovirus. Subsequently, van der Woude2
demonstrated a close association between ANCA and active
Wegener’s granulomatosis, establishing ANCA as a new
biomarker of certain forms of small-vessel systemic vasculitis,
and this was confirmed by Falk3 in other cohorts of patients
with pauci-immune glomerulonephritis (Figure 1). In the
context of vasculitis, ANCAs were found to bind two key
antigens found in neutrophil granules and monocyte
lysosomes, proteinase–3 (PR-3)4 and myeloperoxidase
(MPO).5 The diagnostic value of assays for ANCA is now
widely accepted.6
The pathogenicity of anti-MPO antibodies in vivo and
in vitro has been demonstrated, whereas only convincing
in vitro effects have been found with anti-PR-3 antibodies.7–9
More than 10 years ago a new ANCA target, lysosomal-
associated membrane protein-2 (LAMP-2), was described,
but its significance was unclear.10 Other antigenic targets
have subsequently been recognized, but these are not
generally associated with small-vessel vasculitis, although
certain pathological associations are known: for example,
bactericidal/permeability increasing protein (BPI)-ANCA in
patients with cystic fibrosis11 especially those colonized by
Pseudomonas, and atypical ANCA binding multiple target
antigens,12 which now include tubulin beta and bacterial
FtsZ13 in primary sclerosing cholangitis and inflammatory
bowel disease. Interestingly, many antigenic targets are
leukocyte proteins involved in host defense against infectious
diseases. Indeed LAMP-2, along with LAMP-1, has been
implicated as a critical molecule in maintaining the
microbicidal activity of phagosomes14 and regulating their
maturation. LAMP-2, along with Toll-like receptors, also play
a pivotal part in modulating autophagosome numbers and
maturation, and deficiency of LAMP-2 leads to the
accumulation of autophagosomes in the heart and skeletal
muscles of mice, as well as in patients with Danon disease,
who demonstrate LAMP-2 mutations. Thus, LAMP-2 is
intimately involved in mechanisms regulating microbe
clearance. Importantly, although the association between
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infections and autoimmunity has long been recognized,
direct evidence for causality with regard to renal disease has
mostly been lacking.15,16
Since the original descriptions of ANCA, we have come
to understand more about the pathogenesis of ANCA-
associated vasculitis (AAV), in particular many of the
downstream events that occur once ANCAs are present, such
as how ANCA interacts with leucocytes and endothelial cells,
inducing their activation and effector functions.17 What has
remained unclear is how immune tolerance towards these
ANCA antigens is broken in the first instance. It is therefore
of considerable interest that a recent study by Kain et al.18 has
linked the antigenic target LAMP-2 described earlier,
common to all forms of ANCA-associated glomerulone-
phritis,10 with a mechanism for disease initiation. In
particular, this study reiterated the importance of infectious
agents in the etiology of autoimmune diseases and produced
convincing evidence demonstrating cause and effect. Earlier
clinical observations had implicated bacterial carriage of the
Gram-positive coccus Staphylococcus aureus as a provoking
factor for disease relapses in patients with Wegener’s
granulomatosis.19 In addition, work on the proposed
complementary peptide hypothesis demonstrated a similarity
between amino-acid sequences in S. aureus and a comple-
mentary PR-3 peptide and, similar to the current study by
Kain, implicated molecular mimicry as a mechanism of
disease initiation.20
Kain et al.10 earlier described LAMP-2, a glycosylated
membrane protein contained within neutrophil granules
along with PR-3 and MPO, as an ANCA target and found
antibodies to LAMP-2 in 14/16 patients with necrotizing
glomerulonephritis.10 However, the importance of these
antibodies has been recognized only now. This study shows
that anti-LAMP-2 antibodies are found in patients with
active AAV and have the potential to be pathogenic, activating
neutrophils and causing microvascular endothelial cell injury
in vitro, as well as inducing a focal segmental necrotizing
glomerulonephritis (FSNGN) when injected into susceptible
rats. In addition, anti-LAMP-2 antibodies recognized a nine-
amino-acid epitope (P4149) with significant homology to a
bacterial fimbrial protein FimH, found in various Gram-
negative bacteria. Interestingly, this LAMP-2 epitope shares
no homology with either MPO or PR-3, and anti-LAMP-2
antibodies do not cross-react with anti-MPO or anti-PR-3
antibodies, nor do they prevent them from binding to their
respective antigens. However, through a series of inhibition
experiments the authors demonstrate that sera containing
anti-LAMP-2 antibodies are prevented from binding the
P4149 epitope by recombinant FimH protein or lysates from
bacteria containing the FimH protein, but not by those that
lack the FimH. Conversely, sera are prevented from binding
FimH protein by LAMP-2.
Finally, to complete the picture, the authors immunized
WKY rats with recombinant FimH protein (or P4149) and
showed ANCA reactivity within the serum, anti-LAMP-2
activity and pauci-immune focal necrotizing glomerulone-
phritis (Figure 2). These data convincingly demonstrate that
FimH proteins can induce anti-LAMP-2 activity, and that
these antibodies can be pathogenic. Linking this with the
human condition, the authors report that almost 70% of
their patients with FSNGN (Figure 1) had recent evidence
of an infection with a fimbriated organism and evidence of
LAMP-2 antibodies, including reactivity to the dominant
P4149 epitope. By contrast, patients with fimbriated bacterial
infections but no renal disease had antibodies to FimH, but
neither anti-LAMP-2 antibodies nor antibodies to the
Figure 1 | Photomicrograph of a renal biopsy from a patient
with active ANCA-associated vasculitis (AAV), demonstrating
crescentic glomerulonephritis and fibrinoid necrosis in the
glomerular tuft. Silver stain. Magnification  400. Courtesy of
Dr Candice Roufosse, Department of Histopathology, Hammersmith
Hospital.
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Figure 2 | Sketch demonstrating the proposed mechanism of
molecular mimicry inducing immune responsiveness to
bacterial fimbrial protein and in turn lysosomal-associated
membrane protein (LAMP-2), resulting in activation of
circulating neutrophils and damage to glomerular endothelial
cells.
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dominant epitope P4149. These findings are intriguing but
slightly confusing, as they suggest that another critical factor
is required to generate anti-LAMP2 reactivity, and that
infection with fimbriated bacteria is not sufficient for
development of pauci-immune FSNGN in patients. This is
not really surprising as Gram-negative infections are
considerably more common than pauci-immune FSNGN,
and other triggers would be expected to be required for
disease to develop. On the other hand, susceptible rats
such as the WKY strain, which are used in many models of
glomerulonephritis, may be more easily provoked into
developing disease with a single stimulus.
Overall these findings are highly significant. These new
data take the association with infectious agents one step
further by describing a potential mechanism for disease
initiation that requires more investigation. Independent
cohorts of patients should be studied for evidence of anti-
LAMP-2 antibodies, anti-FimH, and anti-P4149 reactivity,
and should in addition include larger cohorts of control
subjects with other glomerular diseases. We should also
investigate those ANCA-negative patients with pauci-im-
mune FSNGN to observe whether they demonstrate anti-
LAMP-2 reactivity, and explore the differences between
ANCA-positive patients with limited disease and those with
systemic features including renal involvement. The relation-
ship between anti-MPO, anti-PR-3, and anti-LAMP-2 anti-
bodies needs further investigation to understand why they
co-exist and whether they play a role in inducing each other
through, for example, leukocyte activation. Perhaps their
interaction may help explain why ANCA titers do not always
correlate with disease activity, and why discrepancies between
the anti-MPO/PR-3 ELISA results and ANCA detection by
indirect immunofluorescence on neutrophils are observed in
patients. Additionally, one would predict that T-cell
responses to LAMP-2 and indeed FimH should be detected
at increased frequency in patients with active AAV, as they
have been shown to react with PR-3 and MPO. One issue
with the current study is that the effects of anti-LAMP
antibodies were shown using rabbit or mouse derived
antibodies, not human ones (because of the coexistence of
anti-PR3 and anti-MPO antibodies in the serum samples).
These effects should be confirmed with human anti-LAMP
antibodies, as there may be differences in pathogenic
potential between antibodies from different species even
with similar antigenic targets.
Should we routinely screen for anti-LAMP-2 activity in all
our AAV patients? Not yet, until the specificity and sensitivity
of the antibody are verified, but perhaps we should be saving
sera from such patients to make this analysis possible in the
future. Should we alter our management based on these data?
Again, not until we have more information regarding the
relationship between disease activity and antibody titer,
and the effect of immunosuppression on antibody positivity.
Kain et al. may have finally shed some light on a mechanistic
association between infections and autoimmune pathology
that many have suggested but have not been able to prove.
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